期刊文献+

血管性血友病因子裂解酶功能检测在血栓性血小板减少性紫癜诊断中的意义 被引量:1

Significance of measurement of von Willebrand factor-cleaving protease activity in diagnosis of thrombotic thrombocytopenic purpura
原文传递
导出
摘要 目的建立血栓性血小板减少性紫癜(TTP)的实验诊断方法,并用于TTP患者的诊断。方法将微管透析前、后的正常人混合血浆、TTP患者血浆进行琼脂糖凝胶水平电泳与WesternBlot,分析TTP患者血浆中vWF多聚体的组成变化;以残余胶原结合力检测血管性血友病因子裂解酶(vWF-cp)的活性水平。结果正常人混合血浆的vWF-cp活性为88·79%,4例TTP患者vWF-cp活性分别为8·90%,4·72%,28·73%,10·35%。正常混合血浆透析后只存在小分子量vWF;TTP患者血浆透析前、后的多聚体分布无变化或变化不明显。结论残余胶原结合力测定结合裂解后的vWF多聚体电泳与Western Blot技术可准确分析vWF-cp活性与vWF多聚体结构组成的变化,为TTP诊断提供新的有用的实验诊断方法。 Objective To establish the experimental method for diagnosis of thrombotic thrombocytopenic purpura (TTP). Methods The plasma of the patients with TTP and the normal pooled plasma (NP), which were prepared by either dialysis or not, were involved in the study and the gel eleetrophoresis and Western Blot were performed to investigate the structural difference of vWF multimers in the TTP patients. The yon Willebrand factor-cleaving protease (vWF-ep) activity was analyzed with the residue-collagen binding assay (R-CBA). Results The vWF-Cp aetivity was 88.79% in NP and 8.90%, 4. 72%, 28.73% and 10. 35% in four patients with TTP respectively. In TTP, there was no significant structural difference of vWF multimers in the plasma between before and after dialysis while only low molecular weight vWF was observed in dialyzed NP. Conclusion The combination of the gel eleetrophoresis and Western Blot as well as R-CBA is helpful for the laboratory diagnosis of TTP.
出处 《中华检验医学杂志》 CAS CSCD 北大核心 2006年第5期414-416,共3页 Chinese Journal of Laboratory Medicine
基金 国家自然科学基金资助项目(30470732) 江苏省"135工程"重点学科开放课题基金资助项目(135XY0404)
关键词 von Willebrand病 紫癜 血栓性血小板减少性 yon Willebrand disease Purpura,thrombotic thrombocytopenic
  • 相关文献

参考文献2

二级参考文献13

  • 1Han-Mou Tsai. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura[J] 2002,Journal of Molecular Medicine(10):639~647
  • 2Masami Mitani,Yoshiyuki Kuwabara,Hiroyuki Kawamura,Atsushi Sato,Kouji Hattori,Yoshitaka Fujii. Significance of Plasma Thymosin α1 Measurements in Gastric Cancer Patients[J] 2000,World Journal of Surgery(4):455~458
  • 3OleksowiczL,BhagwatiN,DeLeonFernandez,etal.DificientactivityofvonWillebrand’sfactor cleavingproteasein patientswithdisseminatedmalignancies[].Cancer Research.1999
  • 4StudtJD,BhmM,BuddeU ,etal.MeasurementofvonWillebrandfactor cleavingprotease (ADAMTS13)activityin plasma:amulticentercomparisonofdifferentassaymethods[].JThrombHaemost.2003
  • 5Furlan M,Robles R,Galbusera M,et al.von Willebrand factorcleaving protease in thrombotic thrombocyto-penic purpura and the hemolytic-uremic syndrome[].The New England Journal of Medicine.1998
  • 6Tsai HM,Lian EC.Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura[].The New England Journal of Medicine.1998
  • 7Zheng X,Chung D,Takayama T K,et al.Structure of von Willebrand factor-Cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura[].Journal of Biological Chemistry.2001
  • 8Moake JL.Thrombotic microangiopathies[].The New England Journal of Medicine.2002
  • 9Mannucci PM,Karimi M,Mosalaei A,et al.Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS13 (von Willebrand factor cleaving protease)[].Haematologica.2003
  • 10Xi X,Ruan C,Li P, et al.Use of monoclonal antibodies in enzyme-linked immunoassay for von Willebrand factor[].Chin J Med Lab Sci.1988

共引文献15

同被引文献4

  • 1SADLER J E. Von Willebrand factor,ADAMTS13,and thrombotic thrombocytopenic purpura[J]. Blood,2008,112:11-18.
  • 2SADLER J E, PONCZ M. Antibody-mediated throm-botic disorders : thrombotic thrombocytopenic purpuraand heparin-induced thrombocytopenia[M]//KAUS-HANSKY K,LICHTMAN M A’BEULTER E,et al.Williams Hematology. 8th ed. The McGraw-HillCompanies. Inc,2010:2163 - 2183.
  • 3KOKAME K,NOBE Y’KOKUBO Y,et al. FRETS-VWF73,a first fluorogenic substrate for ADAMTS13assay[J]. Br J Haematol, 2005,129 :93 -100.
  • 4BRESIN E,GASTOLDI S,DAINA E,et al. Ritux-imab as pre-emptive treatment in patients with throm-botic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies [J]. Thromb Haemost,2009,101:233-238.

引证文献1

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部